LCS
AURA icon

Levin Capital Strategies’s Aura Biosciences AURA Stock Holding History

Levin Capital Strategies’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-50,000
Closed -$446K – 226
2024
Q3 		$446K Buy
+50,000
New +$429K 0.04% 134

Other funds holding AURA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
TGAM
TBH Global Asset Management Brentwood, Tennessee $546M AUM 26.68% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Levin Capital Strategies's AURA Position: Q2 2026 in Review

Levin Capital Strategies reduced its Aura Biosciences (AURA) stake by 11% in Q2 2026, selling an estimated $739K and leaving 838,067 shares worth $5.95M. The position accounts for 0.4% of the portfolio, ranked #67.

Levin Capital Strategies first reported a position in AURA in Q1 2023 and has held it in 14 quarters since. The position peaked at $10.3M in Q4 2024. 44 funds tracked by Wall St. Rank hold AURA as of Q2 2026.

  • Levin Capital Strategies held 838,067 shares of Aura Biosciences worth $5.95M as of Q2 2026.
  • Levin Capital Strategies sold 103,333 Aura Biosciences shares in Q2 2026, an estimated $739K.
  • Aura Biosciences made up 0.4% of Levin Capital Strategies's portfolio in Q2 2026, its #67 holding.
  • Levin Capital Strategies first reported a position in Aura Biosciences in Q1 2023 and has held it in 14 quarters since.
  • Levin Capital Strategies's Aura Biosciences position peaked at $10.3M in Q4 2024.
  • 44 funds tracked by Wall St. Rank held Aura Biosciences as of Q2 2026.

Based on Levin Capital Strategies's 13F filing for Q2 2026, filed 31 Jul 2026.